Sfoglia per Autore
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
2021-01-01 Rigolin G.M.; Cavazzini F.; Piciocchi A.; Arena V.; Visentin A.; Reda G.; Zamprogna G.; Cibien F.; Vitagliano O.; Coscia M.; Farina L.; Gaidano G.; Murru R.; Varettoni M.; Paolini R.; Sportoletti P.; Pietrasanta D.; Molinari A.L.; Quaglia F.M.; Laurenti L.; Marasca R.; Marchetti M.; Mauro F.R.; Crea E.; Vignetti M.; Gentile M.; Montillo M.; Foa R.; Cuneo A.
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia
2021-01-01 Vitale C.; Boccellato E.; Comba L.; Jones R.; Perutelli F.; Griggio V.; Coscia M.
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll
2021-01-01 Vitale C.; Griggio V.; Riganti C.; Todaro M.; Kopecka J.; Jones R.; Salvetti C.; Boccellato E.; Perutelli F.; Voena C.; Godio L.; Boccadoro M.; Coscia M.
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence
2020-01-01 L Scarfò, S Bonfiglio, L A Sutton, V Ljungstrom, T Pandzic, D Cortese, G Gaidano, L Trentin, L Bonello, G Reda, P Panayiotidis, F Forconi, N Stavroyianni, C Bödör, C Tam, S Iyengar, A Österborg, M Coscia, L Ysebaert, O Jaksic, I Ringshausen, S Mulligan, A Tedeschi, V Strugov, Z Davis, C Pavlovsky, R Marasca, A Capasso, P Ranghetti, K Stamatopoulos, R Rosenquist, P Ghia
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape
2020-01-01 Morelli F, Innocenti I, Autore F, Fresa F, Tomasso A, Piciocchi A, Frustaci AM, Trentin L, Mauro FR, Schiattone L, Visentin A, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Vitale C, Sportoletti P, Murru R, Levato L, Gentile M, D’Arena G, Coscia M, Villa MR, Fontana R, Efremov D, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy
2020-01-01 Porrazzo M.; Nicolai E.; Riminucci M.; Vitale C.; Coscia M.; De Paoli L.; Rago A.; Buscicchio G.; Maestrini G.; Ligia S.; Di Prima A.; Corsi A.; Caronna R.; Gaidano G.; Mauro F.R.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
2020-01-01 Herishanu Y.; Shaulov A.; Fineman R.; Basic-Kinda S.; Aviv A.; Wasik-Szczepanek E.; Jaksic O.; Zdrenghea M.; Greenbaum U.; Mandac I.; Simkovic M.; Morawska M.; Benjamini O.; Spacek M.; Nemets A.; Bairey O.; Trentin L.; Ruchlemer R.; Laurenti L.; Stanca Ciocan O.; Doubek M.; Shvidel L.; Dali N.; Miras F.; De Meuter A.; Dimou M.; Mauro F.R.; Coscia M.; Bumbea H.; Szasz R.; Tadmor T.; Gutwein O.; Gentile M.; Scarfo L.; Tedeschi A.; Sportoletti P.; Gimeno Vazquez E.; Marquet J.; Assouline S.; Papaioannou M.; Braester A.; Levato L.; Gregor M.; Rigolin G.M.; Loscertales J.; Medina Perez A.; Nijziel M.R.; Popov V.M.; Collado R.; Slavutsky I.; Itchaki G.; Ringelstein S.; Goldschmidt N.; Perry C.; Levi S.; Polliack A.; Ghia P.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
2020-01-01 Gentile M.; Martino E.A.; Visentin A.; Coscia M.; Reda G.; Sportoletti P.; Mauro F.R.; Laurenti L.; Varettoni M.; Murru R.; Chiarenza A.; Vigna E.; Mendicino F.; Lucia E.; Bossio S.; Recchia A.G.; Moia R.; Pietrasanta D.; Loseto G.; Consoli U.; Scortechini I.; Rossi F.M.; Zucchetto A.; Al-Janazreh H.; Vitale C.; Tripepi G.; D'Arrigo G.; Angeletti I.; Bomben R.; Neri A.; Cutrona G.; Fronza G.; Di Raimondo F.; Gaidano G.; Cuneo A.; Foa R.; Ferrarini M.; Trentin L.; Gattei V.; Morabito F.
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
2020-01-01 Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M.
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs
2020-01-01 Vitale C.; Montalbano M.C.; Salvetti C.; Boccellato E.; Griggio V.; Boccadoro M.; Coscia M.
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)
2020-01-01 Mauro F.R.; Giannarelli D.; Galluzzo C.M.; Vitale C.; Visentin A.; Riemma C.; Rosati S.; Porrazzo M.; Pepe S.; Coscia M.; Trentin L.; Gentile M.; Raponi S.; Micozzi A.; Gentile G.; Baroncelli S.
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation
2020-01-01 Farina L.; Barretta F.; Scarfo L.; Bruno B.; Patriarca F.; Frustaci A.M.; Coscia M.; Salvetti C.; Quaresmini G.; Fanin R.; Onida F.; Magagnoli M.; Zallio F.; Vallisa D.; Reda G.; Ferrario A.; Corradini P.; Montillo M.
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
2020-01-01 Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
2020-01-01 Cerrano M.; Ruella M.; Perales M.-A.; Vitale C.; Faraci D.G.; Giaccone L.; Coscia M.; Maloy M.; Sanchez-Escamilla M.; Elsabah H.; Fadul A.; Maffini E.; Pittari G.; Bruno B.
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
2020-01-01 Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M.
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights
2020-01-01 Salvetti C, Vitale C, Griggio V, Drandi D, Bonello L, Cavallo F, Bomben R, Gattei V, Zamò A, Coscia M
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib
2020-01-01 Perutelli F, Griggio V, Vitale C, Mauro FR, Salvetti C, Boccellato E, Pietrasanta D, Vincelli ID, Ghia P, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target
2020-01-01 Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia
2020-01-01 Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M
Editorial: CAR T-Cell therapies in hematologic tumors.
2020-01-01 coscia marta, Bruno Benedetto, Neelapu Sattva
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group | 2021 | Rigolin G.M.; Cavazzini F.; Piciocchi A.; Arena V.; Visentin A.; Reda G.; Zamprogna G.; Cibien F.; Vitagliano O.; Coscia M.; Farina L.; Gaidano G.; Murru R.; Varettoni M.; Paolini R.; Sportoletti P.; Pietrasanta D.; Molinari A.L.; Quaglia F.M.; Laurenti L.; Marasca R.; Marchetti M.; Mauro F.R.; Crea E.; Vignetti M.; Gentile M.; Montillo M.; Foa R.; Cuneo A. | |
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia | 2021 | Vitale C.; Boccellato E.; Comba L.; Jones R.; Perutelli F.; Griggio V.; Coscia M. | |
Targeting hif-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in cll | 2021 | Vitale C.; Griggio V.; Riganti C.; Todaro M.; Kopecka J.; Jones R.; Salvetti C.; Boccellato E.; Perutelli F.; Voena C.; Godio L.; Boccadoro M.; Coscia M. | |
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence | 2020 | L Scarfò, S Bonfiglio, L A Sutton, V Ljungstrom, T Pandzic, D Cortese, G Gaidano, L Trentin, L Bonello, G Reda, P Panayiotidis, F Forconi, N Stavroyianni, C Bödör, C Tam, S Iyengar, A Österborg, M Coscia, L Ysebaert, O Jaksic, I Ringshausen, S Mulligan, A Tedeschi, V Strugov, Z Davis, C Pavlovsky, R Marasca, A Capasso, P Ranghetti, K Stamatopoulos, R Rosenquist, P Ghia | |
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape | 2020 | Morelli F, Innocenti I, Autore F, Fresa F, Tomasso A, Piciocchi A, Frustaci AM, Trentin L, Mauro FR, Schiattone L, Visentin A, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Vitale C, Sportoletti P, Murru R, Levato L, Gentile M, D’Arena G, Coscia M, Villa MR, Fontana R, Efremov D, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L | |
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy | 2020 | Porrazzo M.; Nicolai E.; Riminucci M.; Vitale C.; Coscia M.; De Paoli L.; Rago A.; Buscicchio G.; Maestrini G.; Ligia S.; Di Prima A.; Corsi A.; Caronna R.; Gaidano G.; Mauro F.R. | |
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group | 2020 | Herishanu Y.; Shaulov A.; Fineman R.; Basic-Kinda S.; Aviv A.; Wasik-Szczepanek E.; Jaksic O.; Zdrenghea M.; Greenbaum U.; Mandac I.; Simkovic M.; Morawska M.; Benjamini O.; Spacek M.; Nemets A.; Bairey O.; Trentin L.; Ruchlemer R.; Laurenti L.; Stanca Ciocan O.; Doubek M.; Shvidel L.; Dali N.; Miras F.; De Meuter A.; Dimou M.; Mauro F.R.; Coscia M.; Bumbea H.; Szasz R.; Tadmor T.; Gutwein O.; Gentile M.; Scarfo L.; Tedeschi A.; Sportoletti P.; Gimeno Vazquez E.; Marquet J.; Assouline S.; Papaioannou M.; Braester A.; Levato L.; Gregor M.; Rigolin G.M.; Loscertales J.; Medina Perez A.; Nijziel M.R.; Popov V.M.; Collado R.; Slavutsky I.; Itchaki G.; Ringelstein S.; Goldschmidt N.; Perry C.; Levi S.; Polliack A.; Ghia P. | |
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab | 2020 | Gentile M.; Martino E.A.; Visentin A.; Coscia M.; Reda G.; Sportoletti P.; Mauro F.R.; Laurenti L.; Varettoni M.; Murru R.; Chiarenza A.; Vigna E.; Mendicino F.; Lucia E.; Bossio S.; Recchia A.G.; Moia R.; Pietrasanta D.; Loseto G.; Consoli U.; Scortechini I.; Rossi F.M.; Zucchetto A.; Al-Janazreh H.; Vitale C.; Tripepi G.; D'Arrigo G.; Angeletti I.; Bomben R.; Neri A.; Cutrona G.; Fronza G.; Di Raimondo F.; Gaidano G.; Cuneo A.; Foa R.; Ferrarini M.; Trentin L.; Gattei V.; Morabito F. | |
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation | 2020 | Apolito V.; Giaccone L.; Ferrero S.; Larocca A.; Cavallo F.; Coscia M.; Beggiato E.; Butera S.; Martella F.; Dainese C.; Cetani G.; Scaldaferri M.; Cattel F.; Boccadoro M.; Ferrero D.; Bruno B.; Cerrano M. | |
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs | 2020 | Vitale C.; Montalbano M.C.; Salvetti C.; Boccellato E.; Griggio V.; Boccadoro M.; Coscia M. | |
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) | 2020 | Mauro F.R.; Giannarelli D.; Galluzzo C.M.; Vitale C.; Visentin A.; Riemma C.; Rosati S.; Porrazzo M.; Pepe S.; Coscia M.; Trentin L.; Gentile M.; Raponi S.; Micozzi A.; Gentile G.; Baroncelli S. | |
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation | 2020 | Farina L.; Barretta F.; Scarfo L.; Bruno B.; Patriarca F.; Frustaci A.M.; Coscia M.; Salvetti C.; Quaresmini G.; Fanin R.; Onida F.; Magagnoli M.; Zallio F.; Vallisa D.; Reda G.; Ferrario A.; Corradini P.; Montillo M. | |
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia | 2020 | Griggio, Valentina; Vitale, Candida; Todaro, Maria; Riganti, Chiara; Kopecka, Joanna; Salvetti, Chiara; Bomben, Riccardo; Dal Bo, Michele; Magliulo, Daniela; Rossi, Davide; Pozzato, Gabriele; Bonello, Lisa; Marchetti, Monia; Omedè, Paola; Kodipad, Ahad Ahmed; Laurenti, Luca; Del Poeta, Giovanni; Mauro, Francesca Romana; Bernardi, Rosa; Zenz, Thorsten; Gattei, Valter; Gaidano, Gianluca; Foà, Robin; Massaia, Massimo; Boccadoro, Mario; Coscia, Marta | |
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice | 2020 | Cerrano M.; Ruella M.; Perales M.-A.; Vitale C.; Faraci D.G.; Giaccone L.; Coscia M.; Maloy M.; Sanchez-Escamilla M.; Elsabah H.; Fadul A.; Maffini E.; Pittari G.; Bruno B. | |
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells | 2020 | Vitale C, Todaro M, Griggio V, Salvetti C, Riganti C, Landesman Y, Boccadoro M, Coscia M. | |
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights | 2020 | Salvetti C, Vitale C, Griggio V, Drandi D, Bonello L, Cavallo F, Bomben R, Gattei V, Zamò A, Coscia M | |
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib | 2020 | Perutelli F, Griggio V, Vitale C, Mauro FR, Salvetti C, Boccellato E, Pietrasanta D, Vincelli ID, Ghia P, Del Poeta G, Gaidano G, Gattei V, Foà R, Boccadoro M, Coscia M | |
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target | 2020 | Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Rossi D, Pozzato G, Marchetti M, Omedé P, Bonello L, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Gattei V, Gaidano G, Foa’ R, Massaia M, Boccadoro M, Coscia M | |
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia | 2020 | Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M | |
Editorial: CAR T-Cell therapies in hematologic tumors. | 2020 | coscia marta, Bruno Benedetto, Neelapu Sattva |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile